NKGen Biotech Accounts Payable

NKGen Biotech posts a accounts payable of $0 as of March 2025. That compares with $13M in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, NKGen Biotech's accounts payable was $13M. The latest reading is $0 — a 100.0% year-over-year decrease (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of NKGen Biotech's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NKGN's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; NKGen Biotech's other metric pages and overview cover the third.